Interleukin-12 inhibits cell invasion in choriocarcinoma

ZHOU ZHANG, QIAN XU, CHANGHUA SHI and YUHONG LI

Department of Basic Medicine, Chengde Medical College, Chengde 067000, Hebei, P.R. China

Received January 4, 2012; Accepted February 23, 2012

DOI: 10.3892/ijmm.2012.960

Abstract. Gestational trophoblastic disease (GTD) is a unique disease that arises from allografting of the conceptus, and has a characteristic morphology and biological behavior. It encompasses a spectrum of interrelated diseases, including hydatidiform mole, invasive mole, choriocarcinoma and placental-site trophoblastic tumor, but its pathogenesis remains unrevealed. Particularly, choriocarcinoma is a highly malignant tumor with poor prognosis. In this study, we cultured the human choriocarcinoma cell line JEG-3 in vitro. After treating the cells with different doses of interleukin (IL)-12, the cell invasion was observed. We also detected the expression of matrix metalloproteinases (MMP)-9 and tissue inhibitors of metalloproteinases (TIMP)-1 and the cell cycle of JEG-3 cells. Our data indicated that IL-12 inhibits cell invasion in a dose- and time-dependent manner through regulating the expression of MMP-9 and TIMP-1. In addition, treatment with IL-12 redistributes the phases of the cell cycle in JEG-3 cells. These findings suggest an antitumor role of IL-12 in choriocarcinoma, with far reaching possibilities for understanding the mechanisms of IL-12.

Introduction

The GTD is a rare disease that arises from allografting of the conceptus, and characterized by an abnormal proliferation, local invasion and widespread metastasis. It encompasses a spectrum of interrelated diseases, including hydatidiform mole, invasive mole, choriocarcinoma and placental-site trophoblastic tumor (1), but choriocarcinoma is the unique highly malignant tumor originated in mononuclear cytotrophoblasts and multinucleated syncytiotrophoblasts (2). As other tumors, abnormal proliferation and invasion of trophoblast cells can lead to the development of choriocarcinoma. Matrix metalloproteinases (MMPs) and the tissue inhibitors of metalloproteinases (TIMPs) as important factors related to the degradation of extracellular matrix (ECM), taking part in invasion and metastasis of tumor cells (3,4). However, different from tumor of a host tissue, choriocarcinoma can occur after a pregnancy and during implantation; trophoblastic invasion is strictly regulated temporospatially (5). As a component of germ cell tumors or a poorly differentiated somatic carcinoma with distinct clinical features, choriocarcinoma plays the role of stem cells (6). As the preferred medication, the acquired resistance of 5-fluorouracil is too serious to lead the curative effect of high-risk patients with choriocarcinoma (7). Since conventional treatments including surgery and chemotherapy often fail, novel therapeutic strategies are needed. In particular, cytokine therapy has fostered the progress of immunotherapy. In recent years, the immunoregulatory function and antitumor activity of interleukin (IL)-12 is gradually becoming a research hotspot. Some promising results have been obtained for other tumors (8-10).

The IL-12 is a cytokine that exerts immunoregulatory effects on T cells and NK cells, and is produced by antigen presenting cells, such as macrophages and mononuclear cells. IL-12 was found to be effective for promoting cell-mediated immunity and antitumor effects in mouse tumor models, human tumor tissues, and in cells of a variety of infections diseases (11-14), therefore, it can be used for other tumors, but reports on choriocarcinoma research are scarce. It has been demonstrated that IL-12 inhibited the proliferation and invasion of choriocarcinoma JEG-3 cells only to a small extent in 1,000 pg/ml and for 48 h (15), whereas to our knowledge, no studies to date have demonstrated the function of higher doses and longer action times of IL-12. Furthermore, it is necessary to elucidate because our earlier studies (16,17) have proved that the anti-proliferation of IL-12 was inversely correlated with concentrations in JEG-3 cells with higher doses, this result was not exactly consistent with that of 0-1,000 pg/ml for 48 h (15).

Based on these observations, we aimed to investigate the effect of different higher concentrations and different longer action times of IL-12 on cell cycle and invasion in JEG-3 cells, at the same time, we investigated the expressions of MMP-9 and TIMP-1 for possible mechanisms of invasion, to provide theoretical basis for pathogenesis and new insights into clinical early treatment of choriocarcinoma.

Materials and methods

Materials. JEG-3 cells were purchased from the State Key Laboratory of Reproductive Biology (SKLRB), affiliated to Institute of Zoology (IOZ), Chinese Academy of Sciences (CAS).
Table I. PCR primers used in reaction.

<table>
<thead>
<tr>
<th>Target</th>
<th>Primer sequences (5’-3’)</th>
<th>Product size (bp)</th>
<th>Annealing temperature (˚C)</th>
</tr>
</thead>
</table>
| MMP-9    | F: TCG TGC CTC TGC CCA TAG G  
R: CAC CCT TGT GCT CTT CCC TG  | 463              | 57                        |
| TIMP-1   | F: GTT GTT GTG GTG GAT AG  
R: TGT GGG ACC TGT GGA AGT A  | 265              | 58                        |
| β-actin  | F: AGC GGG AAA TCG TGC GTG AC  
R: ACA TCT GCT GGA AGG TGG AC  | 453              | 58                        |

Figure 1. The JEG-3 cells were treated with IL-12 for 48 h, then their invasive capacity was detected using Transwell invasion assay, the total number of transmigrated cells were counted under a light microscope. Exogenous IL-12 specifically inhibited the invasive capacity of JEG-3 cells. The data are presented as the mean ± SD (n=5; *P<0.05 compared with IL-12 0 µg/l; **P<0.05 compared with the other groups, except 0 µg/l.

**JEG-3 cell culture.** JEG-3 cells were cultured in an incubator with 5% CO₂ on 37˚C in Dulbecco’s modified Eagle’s medium (DMEM) (Gibco-BRL, USA) with 10% fetal bovine serum (FBS) (Hanzhou Sijiqing Biological Engineering Materials Co., Ltd., China), 100 mM pyruvic acid Na, 200 mM glutamine, 100 U/ml penicillin and 100 µg/ml streptomycin. Cells were not subcultured with 0.25% trypsin and 0.02% EDTA until the cell growth reached 70-80%, and the density of subcultured cells was 1:2 to 1:4.

**Transwell invasion assay.** Cell invasion assay was performed using 6.5 mm transwell inserts with polycarbonate membrane filters containing 8-µm pores (Corning Inc., Acton, MA, USA), and then a thin layer of growth factor-reduced diluted Matrigel (BD Biosciences, NJ, USA) (18), was incubated on top of membranes at 37˚C and the inserts were placed into 24-well culture plates containing 500 µl of DMEM supplemented with 20% FBS. After gel formation, 2X10⁴ cells/200 µl of serum-free DMEM, respectively, containing 0, 5, 10, 25, 50, 100, 200 µg/l IL-12 were plated in the upper chambers and cultured for 24 h. Cells from the upper surface of the Matrigel layer were rubbed off gently with cotton swab and then naturally dried, the invading cells attached to the membrane were fixed in 4% paraformaldehyde for 10 min and stained with hematoxylin (19). The total number of transmigrated cells were determined by counting the number of dying cells in 10 randomly selected fields of vision at x200 magnification with a light microscope. Cell invasion was performed on five independent occasions.

**Reverse transcription (RT)-PCR.** The cells were incubated in 6-well plates with the density of 3x10⁵/ml and then allowed to grow for 48 h, followed by culture with serum-free DMEM for 24 h. After cell synchronization, different concentrations human recombinant IL-12 were added into each well in the following groups: 0, 5, 10, 25, 50, 100, 200 µg/l, and continued incubating for 48 h. Our preliminary experiment demonstrated that 5 µg/l was the most effective stimulative concentration in our experiment range (16). JEG-3 cells were induced with IL-12 5 µg/l for 24, 36, 48 and 72 h, respectively. Total-RNA extraction of JEG-3 cells from each group was isolated with TRIzol reagent (Invitrogen, Carlsbad, CA, USA). RNA was separated by 1% agarose gel electrophoresis and 28S, 18S, 5S bands were detectable. cDNA was synthesized from 1 µg of RNA with oligo(dh)20 primers with the use of the M-MLV first-strand synthesis system kit (Invitrogen). Taq™ kit (Takara Biotechnology Co., Dalian, Liaoning, China) was used for PCR amplification. Primers used are listed in Table I. β-actin was the internal control (20). Amplification conditions were as follows: 94˚C for 2 min, followed by 30 cycles of 94˚C for 30 sec; annealing temperature for 30 sec, and 72˚C for 1 min. PCR product were electrophoresed in 2% agarose gel and photographed using ZF ultraviolet transmission reflection analyzer (Shanghai Jiapeng Technology, Shanghai, China) and gray values were measured by Quantity One-4.6.2 software (Bio-Rad, Hercules, CA, USA). The relative level of target mRNA expression was defined as the ratio of the absorbance of the target band to β-actin band.

**Western blotting assay.** The JEG-3 cells were incubated and then divided into different groups as mentioned above in the method of RT-PCR. Then collected, aschizolysed and centrifuged at 4˚C and 12,000 r/min for 20 min. Supernatant was subsequently removed. Protein concentrations were quantified using the Bicinchoninic acid method. Samples were mixed with buffer together at 95˚C for 10 min, followed by 12% SDS-PAGE electrophoresis at 80-120V for 2 h, and the protein bands were then transferred onto 4 mA/cm² PVDF membrane at 4˚C, blocked with 5% skim milk. The membranes were incubated with the primary antibody for 2 h, then washed with Tris-buffered saline Tween-20 (TBST) 15 min, 10 min, 10 min, respectively and incubated with the secondary antibody for 1 h, washed with TBST for 5 min three times, and then color rendered by Super ECL Plus Luminescence fluid (Applygen
Technologies, Inc., Beijing, China). Images were acquired by scanning, and band gray values were measured by Quantity One-4.6.2 software (Bio-Rad). β-actin was the internal reference, and relative expression rate of the target protein served as the ratio of the absorbance of the target band to β-actin band.

Flow cytometry. After the cells were cultured with the density of 3x10^4/ml for 48 h, then removed the serum and continued culturing for 24 h. 0, 5, 10, 25, 50, 100, 200 µg/l IL-12 was added, respectively, to divide the cells into different groups and cultured for 48 and 72 h. The JEG-3 cells were digested, centrifuged and then washed in PBS, fixed in 70% ethanol at 4˚C for 24 h. The samples were washed in PBS and centrifuged again, then stained with propidium iodide, incubated in 4˚C for 30 min. Flow cytometry (Beckman Coulter, USA) diction was performed after the filtration of the samples through 500 screen mesh copper screen.

Statistical analysis. Statistical analysis was performed using SPSS 11.5 software (IBM SPSS Statistics Server, New York, NY, USA). All measurement data were expressed as mean ± SD, and compared using one-way analysis of variance, following pairwise comparisons of several means between groups were performed using the SNK-q method. A P-value <0.05 was considered statistically significant.

Results

IL-12 restrains the JEG-3 cell invasion. The effect of IL-12 on cell invasion was further assessed (Fig. 1). By transwell invasion assay, compared with 0 µg/l IL-12 group, the transmigrated cells in IL-12 treated groups decreased significantly which indicated reduced invasion (P<0.05). However, upregulation of IL-12 concentration slowed down the suppression ratio of invasion (P<0.05). We found that the most effective dose of IL-12 on blocking cell invasion is low dosage of 5 µg/l.

Effect of IL-12 on the expression of MMP-9 and TIMP-1 at different doses. MMP-9, TIMP-1 mRNA and protein were determined using RT-PCR and western blotting assay, respectively. The JEG-3 cells were treated with IL-12 for 48 h. Compared with untreated cells, the expressions of MMP-9 mRNA and protein in IL-12-treated groups decreased gradually (P<0.05), but upregulation of IL-12 concentration increased the expression of MMP-9 (P<0.05) (Fig. 2A, B, D and E). The
expression of TIMP-1 mRNA and protein in IL-12-treated groups increased (P<0.05), whereas upregulation of IL-12 concentration decreased the expression of TIMP-1 (P<0.05) (Fig. 2A, C, D and F).

**Effect of IL-12 on the expression of MMP-9 and TIMP-1 at different action times.** RT-PCR and western blotting revealed MMP-9 and TIMP-1 mRNA and protein expression on the JEG-3 cells without/with 5 µg/l IL-12 treatment varied depending on the incubation times. The expression of MMP-9 mRNA and protein were reduced gradually (P<0.05) (Fig. 3A, B, D and E). On the other hand, TIMP-1 mRNA and protein expression in JEG-3 cells were significant increased following lengthening of the IL-12 action time (P<0.05) (Fig. 3A, C, D and F).

**IL-12 changes the cell cycle of choriocarcinoma cells.** Flow cytometry analysis showed that compare it with the blank
control group (0 µg/l), the cell cycle of JEG-3 cells in IL-12-treated group was obviously arrested, decreased G2 phase cells were founded in both 48 and 72 h IL-12 treated cells (P<0.05) (Fig. 4). Cells were arrested in S phase at both 48 and 72 h (P<0.05) (Fig. 4), as well as in G1 phase at 72 h (P<0.05) (Fig. 4B).

**Discussion**

Invasion is not only an important biological characteristic of tumors, but also the main factor affecting the cure rate in patients. Through invasion, tumor cells can break the original growing scope and vascular system, continuing to infiltrate the surrounding tissue and enter blood circulation and lymphatic system. Trophoblastic cells act as trophoblast stem cells that differentiate into either syncytiotrophoblasts or villous intermesiated trophoblasts in the process of embryo implantation and placenta formation (21). This distinct histological characteristic may lead trophoblast invasion to differ largely from other tumors, and has its stringent regulation and spatio-temporal restriction, controlled punctually by a complex network system, which is performed by cytokines, growth factors, angiogenesis factors, proteases, and apoptosis regulatory factors.

In this study, we found significantly higher anti-invasion function of IL-12 in JEG-3 cells suggesting that IL-12 may participate in the development of choriocarcinoma. Our observations concur with the role of IL-12 in other malignancies (22-24). Such an anti-invasion ability of IL-12 in JEG-3 cell is not surprising since it has been reported that <1,000 pg/ml dose of IL-12 inhibited the invasion of JEG-3 cells and showed dose-dependent effect with the concentration of IL-12 increasing, the JEG-3 cell invasion was obviously weaken (15). On the contrary, the present study found that when the dose of IL-12 exceeded 5 µg/l, the dose-dependent effect of IL-12 changed. The more dose of IL-12 increased, the stronger the JEG-3 cells invasion ability was, but still lower than normal. Therefore, IL-12 only showed antitumor effect at a stable dose in this study, and there was no evidence suggesting a higher dose. To the best of our knowledge, this is the first report demonstrating such a different antitumor effect of IL-12 with low and high dose on cancer cells. Our findings suggested that IL-12 may be executing its functional roles differently at different dose and environments.

Some animal experiments and clinical research also manifested that a novel alloimmune involving T helper (Th)1-type and Th2-type immunity was important to trophoblast invasion (25-28). In response to trophoblast invasion, myriad of antigen presenting cells and other immune response cells may become activated, a by-product of this activation is the secretion of either a predominant Th1 or Th2 cytokine profile, such as IL-12, and then the balance of Th1 and Th2 is broken, thereby promoting or restraining the development of the tumor. Possibly this is a reason for the antitumor functional role of IL-12. Furthermore, IL-12 indirectly mediated antitumor effects also due to its capability of activating other cell types, such as natural killer T (NKT) cells and natural killer (NK) cells. NKT cells were activated preferentially with low dose of IL-12, but high dose of IL-12 activated NK cells first (29-31) and further reduced its antitumor effect through inducing the number of NKT cells rapidly (32). Involvement of IL-12 at different doses in melanoma producing contrasting effects has been reported (33). Thus, *in vivo or in vitro*, IL-12 may act through many different pathways to produce various biological effects in the development of cancer.

In the choriocarcinoma cell line, we further found that the cell-invasion effect of IL-12 was likely to be mediated through the downregulation of MMP-9 and upregulation of TIMP-1, which are essential for choriocarcinoma cell invasion (34). The MMP family is an important enzyme degrading extracellular matrix, and the TIMP family is a natural inhibitor of MMP. The imbalance of MMPs and TIMPs in the extracellular matrix has been confirmed to relate with a variety of pathological states, especially tumor invasions and metastasis (35-37). Our recent study revealed that MMP-9/TIMP-1 respond to exogenous IL-12 in JEG-3 cells, in a dose- and time-dependent manner, the expression of TIMP-1 increased. IL-12 can promote the expressions of TIMP-1 to inhibit MMP-9, the balance of MMP-9 and TIMP-1 was broken. These observations were consistent with the invasion assay. Our findings are in agreement with reports by several authors on a similar antitumor role of IL-12 mediated by inhibition of the MMPs and promotion of the TIMPs. Based upon the above and previous findings that exogenous IL-12 can inhibit the proliferation of JEG-3 cells (16,17), we conclude that the antitumor role of IL-12 is not only due to its anti-proliferation ability but also dependent on the anti-invasion function.

Moreover, to explore the mechanism of IL-12 in choriocarcinoma, we have adopted flow cytometry to observe the cell cycle in JEG-3 cells after incubation with different doses of IL-12. The anti-proliferation and anti-invasion effects of IL-12 on JEG-3 are probably through the cell arrested at S, or S and G1 phases. The change of cell cycle is found to be essential for restraining the proliferation and reducing the invasion of both human and mouse cancer cells in the development of tumor (38-42). We also demonstrated similar results of IL-12 in JEG-3 cells in this study. IL-12 can affect DNA synthesis of the cells, change the cell cycle and signaling pathways and then make the growth of the JEG-3 cells to arrest at S phase after treatment for 48 h, but after 72 h, G1 and S phases were both arrested. In the regulation of cell generation cycle, G0/G1 check point plays an influential role. The regulator through their positive and negative role in regulating cellular DNA synthesis in S phase, induce cells to arrest in G0/G1 phase to inhibit tumor growth. When the IL-12 action after 48 h was continue, it was found that G1 phase was also arrested and then further affected the proliferation and invasion of the cells.

In summary, our findings suggest an important role of IL-12 in tumor cells, IL-12 can inhibit the proliferation and invasion of JEG-3 cells mediated through the regulation of MMP-9 and TIMP-1 and change the cell cycle. Furthermore, IL-12 exerts various effects between low and high dose, this is the first study to demonstrate a likely role for IL-12 in choriocarcinoma by *in vitro* experiments, but the exact mechanism remains controversial. In addition, IL-12 has shown considerable toxicity (43), therefore, how to correctly exert the antitumor function of IL-12 and reduce the toxicity also needs to be elucidated by more studies. Such findings may assist to provide the basis for the clinical treatment of choriocarcinoma.
IL-12 INHIBITS CELL INVASION IN CHORIOCARCINOMA

References


10. Steding CE, Wu ST, Zhang Y, Jeng MH, Elzeby BD and Kao C: The role of interleukin-12 in modulating myeloid-derived suppressor cells, increasing overall survival and reducing metastasis. Immunology 133: 221-238, 2011.


32. Eberl G and MacDonald HR: Rapid death and regeneration of NKT cells in anti-CD3ε0 or IL-12-treated mice: a major role for bone marrow in NKT cell homeostasis. Immunity 9: 345-353, 1998.


